Rallybio Announces Transformative Reverse Merger with Candid Therapeutics, Existing Shareholders Face Significant Dilution

summarizeSummary

Rallybio Corp announced a reverse merger with Candid Therapeutics, where existing Rallybio shareholders will own only 3.65% of the combined company, alongside a $505.5 million concurrent financing for Candid and uncertain CVRs for Rallybio's legacy assets.

check_boxKey Events

• Proposed Reverse Merger with Candid Therapeutics

  Rallybio entered into a merger agreement with Candid Therapeutics on March 1, 2026. Post-merger, existing Rallybio equityholders are expected to own approximately 3.65% of the combined company, while Candid equityholders (including concurrent financing investors) will own 96.35%.

• Significant Concurrent Financing for Candid

  Candid Therapeutics secured an aggregate commitment of approximately $505.5 million in concurrent financing, which will convert into shares of the combined Rallybio entity.

• Contingent Value Rights (CVRs) for Legacy Assets

  Rallybio shareholders will receive CVRs, entitling them to a pro rata share of net proceeds from the disposition of Rallybio's pre-Merger assets and cash from a July 2025 agreement with Recursion Pharmaceuticals. The company will use commercially reasonable efforts for one year post-closing to monetize these assets.

• RLYB212 Program Discontinued

  In April 2025, Rallybio discontinued its RLYB212 program for the prevention of FNAIT due to Phase 2 clinical trial data showing an inability to achieve target concentrations for efficacy.

auto_awesomeAnalysis

This 10-K filing details a pivotal and highly dilutive strategic shift for Rallybio Corp. The proposed reverse merger with Candid Therapeutics will result in current Rallybio shareholders owning a mere 3.65% of the combined entity, effectively transforming Rallybio into Candid. While Candid secured a substantial $505.5 million in concurrent financing, this capital primarily benefits the new combined company's pipeline, not Rallybio's legacy assets. Existing Rallybio shareholders will receive Contingent Value Rights (CVRs) for their pre-Merger assets, but the value and timing of these payouts are uncertain. This transaction, coupled with the discontinuation of the RLYB212 program and prior workforce reductions, signals a significant restructuring and a challenging outlook for existing Rallybio investors due to the substantial dilution and change in strategic direction. The recent 1-for-8 reverse stock split, while resolving Nasdaq compliance issues, underscores the company's prior stock price weakness.